#raltegravir

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.

People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug inte...

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.

Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...

AbbVie’s ’3D’ regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV

Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hep C.

The FDA has approved revisions to the label of the antiretroviral Kaletra (lopinavir/ritonavir) in order to include new information on...

Important preliminary recommendations involving the use of hepatitis C protease inhibitors among people living with HIV are provided by U.S. D...

Study suggests the integrase inhibitor Isentress (raltegravir) could prevent the accumulation of excess fat in the liver (steatosis)

The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...

In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.

People who switched from a protease inhibitor (PI) to Isentress (raltegravir) did well regardless of whether they switched to a once-daily o...